How China’s rise as a biopharma innovation hub is reshaping global dealmaking strategies
China’s biopharma ecosystem is reshaping how global pharmaceutical companies source innovation, build pipelines and structure deals.
Sponsored
Why Most FDA Warning Letters Share a Single — and Fixable — Root Cause
What drives time-to-randomization in oncology trials?
How DFE Pharma supports confident continuous manufacturing decisions
The rare disease revolution: The state of play for CGTs in orphan diseases
Develop site-centric protocols to optimize enrollment and maximize performance
Remedying the paper trail: Manufacturing a digital route to compliance
How to avoid common contamination control mistakes in new aseptic facilities
